LCE1E Inhibitors

LCE1E inhibitors are a set of chemical compounds that diminish the functional activity of the LCE1E protein through modulation of the NF-kB signaling pathway, which is pivotal in the regulation of skin barrier formation and inflammatory responses. Glycyrrhizic acid functions by inhibiting 11β-hydroxysteroid dehydrogenase type 2, leading to increased cortisol levels that in turn inhibit NF-kB, reducing LCE1E expression. Similarly, curcumin suppresses the NF-kB pathway by inhibiting the IKK complex, while resveratrol and sulforaphane directly inhibit NF-kB activation. Quercetin targets upstream PI3K activity, and BAY 11-7082 blocks the phosphorylation of IκBα, both resulting in lowered NF-kB activity and thus LCE1E expression. Epigallocatechin gallate (EGCG) and parthenolide also inhibit NF-kB activation, with SN50 impeding its nuclear translocation and transcriptional function, culminating in a reduction of LCE1E levels, crucial for the epidermal differentiation complex.

These inhibitors, by targeting diverse aspects of the NF-kB pathway, achieve a concerted downregulation of LCE1E. The antioxidant and NF-kB inhibitor Pyrrolidinedithiocarbamic acid ammonium salt, along with ebselen, repress NF-kB activity to lower LCE1E expression. Caffeic acid phenethyl ester (CAPE) exerts its action by attenuating the transcriptional activity of NF-kB, which is essential for the induction of LCE1E. The collective action of these compounds leads to a comprehensive diminution of LCE1E, despite their differing points of interference within the NF-kB signaling cascade. Thus, the inhibition spectrum ranges from the prevention of nuclear translocation of NF-kB by compounds like SN50 to the blockade of upstream signaling events by agents like quercetin and sulforaphane, all converging to suppress LCE1E, a protein integral to skin barrier integrity and inflammatory response regulation.